Abstract Background A number of clinical trials documented benefits glycoprotein IIb-IIIa inhibitors (GPIs) in the setting acute coronary syndromes (ACS). The advantage reducing thrombotic burden at cost a higher risk bleeding has been evaluated different studies. However, data regarding use GPIs as peri-interventional treatment is lacking. Indeed, current European guidelines may only be consid...
